341 related articles for article (PubMed ID: 12719565)
1. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy.
Frenkel LM; Wang Y; Learn GH; McKernan JL; Ellis GM; Mohan KM; Holte SE; De Vange SM; Pawluk DM; Melvin AJ; Lewis PF; Heath LM; Beck IA; Mahalanabis M; Naugler WE; Tobin NH; Mullins JI
J Virol; 2003 May; 77(10):5721-30. PubMed ID: 12719565
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
[TBL] [Abstract][Full Text] [Related]
4. Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virus.
Tobin NH; Learn GH; Holte SE; Wang Y; Melvin AJ; McKernan JL; Pawluk DM; Mohan KM; Lewis PF; Mullins JI; Frenkel LM
J Virol; 2005 Aug; 79(15):9625-34. PubMed ID: 16014925
[TBL] [Abstract][Full Text] [Related]
5. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
6. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy.
Persaud D; Ray SC; Kajdas J; Ahonkhai A; Siberry GK; Ferguson K; Ziemniak C; Quinn TC; Casazza JP; Zeichner S; Gange SJ; Watson DC
AIDS Res Hum Retroviruses; 2007 Mar; 23(3):381-90. PubMed ID: 17411371
[TBL] [Abstract][Full Text] [Related]
7. Decay of HIV type 1 DNA and development of drug-resistant mutants in patients with primary HIV type 1 infection receiving highly active antiretroviral therapy.
Riva E; Pistello M; Narciso P; D'Offizi G; Isola P; Galati V; Turriziani O; Tozzi V; Vincenzi L; Dianzani F; Antonelli G
AIDS Res Hum Retroviruses; 2001 Nov; 17(17):1599-604. PubMed ID: 11779347
[TBL] [Abstract][Full Text] [Related]
8. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy.
Zhu T; Muthui D; Holte S; Nickle D; Feng F; Brodie S; Hwangbo Y; Mullins JI; Corey L
J Virol; 2002 Jan; 76(2):707-16. PubMed ID: 11752161
[TBL] [Abstract][Full Text] [Related]
9. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads.
Persaud D; Siberry GK; Ahonkhai A; Kajdas J; Monie D; Hutton N; Watson DC; Quinn TC; Ray SC; Siliciano RF
J Virol; 2004 Jan; 78(2):968-79. PubMed ID: 14694128
[TBL] [Abstract][Full Text] [Related]
10. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
11. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
[TBL] [Abstract][Full Text] [Related]
12. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution.
Lambotte O; Chaix ML; Gubler B; Nasreddine N; Wallon C; Goujard C; Rouzioux C; Taoufik Y; Delfraissy JF
AIDS; 2004 May; 18(8):1147-58. PubMed ID: 15166530
[TBL] [Abstract][Full Text] [Related]
13. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).
Stellbrink HJ; van Lunzen J; Westby M; O'Sullivan E; Schneider C; Adam A; Weitner L; Kuhlmann B; Hoffmann C; Fenske S; Aries PS; Degen O; Eggers C; Petersen H; Haag F; Horst HA; Dalhoff K; Möcklinghoff C; Cammack N; Tenner-Racz K; Racz P
AIDS; 2002 Jul; 16(11):1479-87. PubMed ID: 12131185
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.
Ghosn J; Pellegrin I; Goujard C; Deveau C; Viard JP; Galimand J; Harzic M; Tamalet C; Meyer L; Rouzioux C; Chaix ML;
AIDS; 2006 Jan; 20(2):159-70. PubMed ID: 16511408
[TBL] [Abstract][Full Text] [Related]
15. Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.
Bull ME; McKernan JL; Styrchak S; Kraft K; Hitti J; Cohn SE; Tapia K; Deng W; Holte S; Mullins JI; Coombs RW; Frenkel LM
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):557-566. PubMed ID: 30892052
[TBL] [Abstract][Full Text] [Related]
16. Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART.
Wang YM; Dyer WB; Workman C; Wang B; Peng NK; Lachireddy K; Chew CB; Sullivan J; Saksena NK
Curr HIV Res; 2007 Mar; 5(2):235-50. PubMed ID: 17346137
[TBL] [Abstract][Full Text] [Related]
17. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
[TBL] [Abstract][Full Text] [Related]
18. Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy.
Parera M; Ibañez A; Clotet B; Martinez MA
J Infect Dis; 2004 Apr; 189(8):1444-51. PubMed ID: 15073682
[TBL] [Abstract][Full Text] [Related]
19. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
[TBL] [Abstract][Full Text] [Related]
20. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
Saitoh A; Fenton T; Alvero C; Fletcher CV; Spector SA
Antimicrob Agents Chemother; 2007 Dec; 51(12):4236-42. PubMed ID: 17893156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
